A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.

Sébastien PerreaultValérie LaroucheUri TaboriCynthia HawkinSarah LippéBenjamin EllezamJean-Claude DécarieYves ThéoretMarie-Élaine MétrasSerge SultanÉdith CantinMarie-Ève RouthierMaxime CaruGeneviève LegaultÉric BouffetLucie Lafay-CousinJuliette HukinCraig ErkerNada Jabado

Published in: BMC cancer (2019)

ClinicalTrials.gov Identifier: NCT03363217 December 6, 2017.

Keyphrases

signaling pathway
pi k akt
open label
oxidative stress
double blind
placebo controlled
randomized controlled trial
clinical trial